InnoCan Pharma Beheer

Beheer criteriumcontroles 3/4

De CEO InnoCan Pharma is Iris Bincovich, benoemd in Jan2018, heeft een ambtstermijn van 6.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 337.00K, bestaande uit 79.5% salaris en 20.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.8% van de aandelen van het bedrijf, ter waarde CA$ 1.08M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.3 jaar en 5 jaar.

Belangrijke informatie

Iris Bincovich

Algemeen directeur

US$337.0k

Totale compensatie

Percentage CEO-salaris	79.5%
Dienstverband CEO	6.8yrs
Eigendom CEO	1.8%
Management gemiddelde ambtstermijn	5.3yrs
Gemiddelde ambtstermijn bestuur	5yrs

Recente managementupdates

It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

May 04

Recent updates

We're Hopeful That InnoCan Pharma (CSE:INNO) Will Use Its Cash Wisely

Aug 09

It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

May 04

Analyse CEO-vergoeding

Hoe is Iris Bincovich's beloning veranderd ten opzichte van InnoCan Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$3m
Jun 30 2024	n/a	n/a	-US$4m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$337k	US$268k	-US$5m
Sep 30 2023	n/a	n/a	-US$5m
Jun 30 2023	n/a	n/a	-US$3m
Mar 31 2023	n/a	n/a	-US$4m
Dec 31 2022	US$401k	US$291k	-US$4m
Sep 30 2022	n/a	n/a	-US$3m
Jun 30 2022	n/a	n/a	-US$7m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$645k	US$300k	-US$10m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$14m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$361k	US$223k	-US$10m
Sep 30 2020	n/a	n/a	-US$3m
Jun 30 2020	n/a	n/a	-US$5m
Mar 31 2020	n/a	n/a	-US$3m
Dec 31 2019	US$384k	US$219k	-US$3m
Sep 30 2019	n/a	n/a	-US$6m
Dec 31 2018	US$165k	US$54k	-US$2m

Compensatie versus markt: De totale vergoeding ($USD 337.00K ) Iris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 169.25K ).

Compensatie versus inkomsten: De vergoeding van Iris is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Iris Bincovich (54 yo)

6.8yrs

Tenure

US$337,000

Compensatie

Mrs. Iris Bincovich has been Member of Advisory Board at Ayurcann Holdings Corp. since May 2021. Mrs. Bincovich has been the Chief Executive Officer at InnoCan Pharma Corporation since January 2018 and has...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ron Mayron	Executive Chairman	5.2yrs	US$136.00k	2.29% CA$ 1.4m
Iris Bincovich	CEO & Director	6.8yrs	US$337.00k	1.8% CA$ 1.1m
Nelson Halpern	Chief Financial Officer	5.8yrs	US$64.00k	0.11% CA$ 63.8k
Roni Kamhi	COO & CEO of BI Sky Global and Director	2.3yrs	US$230.00k	0.15% CA$ 93.3k
Eyal Flom	Director & Company Secretary	4.8yrs	geen gegevens	0.89% CA$ 536.1k
Yoram Drucker	Founder & Executive VP of Business Development	no data	US$173.00k	geen gegevens

5.3yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van INNO is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ron Mayron	Executive Chairman	5.2yrs	US$136.00k	2.29% CA$ 1.4m
Iris Bincovich	CEO & Director	5.2yrs	US$337.00k	1.8% CA$ 1.1m
Roni Kamhi	COO & CEO of BI Sky Global and Director	less than a year	US$230.00k	0.15% CA$ 93.3k
Eyal Flom	Director & Company Secretary	5.2yrs	geen gegevens	0.89% CA$ 536.1k
Izhar Shay	Member of Advisory Committee	3.3yrs	geen gegevens	geen gegevens
Peter Bloch	Independent Director	4.8yrs	geen gegevens	0% CA$ 0
Joseph Pergolizzi	Member of Scientific Advisory Board	1.2yrs	geen gegevens	geen gegevens
Yechezkel Barenholz	Scientific Advisor	no data	geen gegevens	geen gegevens
Joshua Lintern	Independent Director	5.2yrs	geen gegevens	0.071% CA$ 42.8k
Ralph C. Bossino	Director	5.2yrs	geen gegevens	0.11% CA$ 65.8k
Josef Geldwert	Scientific Advisor	no data	geen gegevens	geen gegevens
Mitchell Kline	Member of Scientific Advisory Committee	3.7yrs	geen gegevens	geen gegevens

5.0yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van INNO wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).

InnoCan Pharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

CEO & Director exercised options to buy CA$53k worth of stock.

CEO & Director exercised options to buy CA$53k worth of stock.

It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

InnoCan Pharma Corporation, Annual General Meeting, May 09, 2024

InnoCan Pharma Corporation Announces Appointment of Dr. Joseph V. Pergolizzi to its Scientific Advisory Board

Innocan Pharma Corporation Announces the Addition of Givi Topchishvili, to Advisory Committee, as A Business Strategy Adviser

Recent updates

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.008 loss in 3Q 2023)

Innocan Pharma Corporation's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs

CEO & Director exercised options to buy CA$53k worth of stock.

CEO & Director exercised options to buy CA$53k worth of stock.

InnoCan Pharma Corporation announced that it has received CAD 1.10566 million in funding

InnoCan Pharma Corporation announced that it expects to receive CAD 0.88 million in funding

Second quarter 2024 earnings released: EPS: US$0.001 (vs US$0.002 loss in 2Q 2023)

We're Hopeful That InnoCan Pharma (CSE:INNO) Will Use Its Cash Wisely

Innocan Pharma Corporation Submits Investigational New Animal Drug Application to FDA's Veterinary Center

First quarter 2024 earnings released: US$0.007 loss per share (vs US$0.005 loss in 1Q 2023)

Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey

It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

Full year 2023 earnings released: US$0.018 loss per share (vs US$0.015 loss in FY 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.98821 million in funding

InnoCan Pharma Corporation, Annual General Meeting, May 09, 2024

InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding

Third quarter 2023 earnings released: US$0.008 loss per share (vs US$0.001 loss in 3Q 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.627682 million in funding

InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding

InnoCan Pharma Corporation Announces Appointment of Dr. Joseph V. Pergolizzi to its Scientific Advisory Board

Second quarter 2023 earnings released: US$0.002 loss per share (vs US$0.007 loss in 2Q 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.934239 million in funding

New minor risk - Shareholder dilution

InnoCan Pharma Corporation announced that it expects to receive CAD 1.934239 million in funding

New minor risk - Shareholder dilution

InnoCan Pharma Corporation announced that it has received CAD 3.9606 million in funding

Innocan Pharma Corporation Submits New Patent Applications for Advanced Pain Relief Technology

First quarter 2023 earnings released: US$0.005 loss per share (vs US$0.003 loss in 1Q 2022)

InnoCan Pharma Corporation Announces Successful Treatment of Billy with Liposomal-CBD Injection in Pre-Clinical Trial

Full year 2022 earnings released: US$0.015 loss per share (vs US$0.045 loss in FY 2021)

InnoCan Pharma Corporation announced that it has received CAD 0.4955 million in funding

Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

Third quarter 2022 earnings released: US$0.001 loss per share (vs US$0.016 loss in 3Q 2021)

Innocan Pharma Corporation Announces the Addition of Givi Topchishvili, to Advisory Committee, as A Business Strategy Adviser

Less than half of directors are independent

Innocan Pharma Corporation Announces Additional Positive Results in New Preclinical Trial Involving A Dog with Refractory Epilepsy

Second quarter 2022 earnings released

InnoCan Pharma Corporation Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

We Think InnoCan Pharma (CSE:INNO) Can Afford To Drive Business Growth

InnoCan Pharma Corporation Announces Results Approaches 100% Bioavailability Following Subcutaneous Injection of Its CBD Proprietary LPT Delivery System in A Clinical Study Conducted on Dogs Suffering from Pain

InnoCan Pharma Corporation Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss

Innocan Pharma Corporation Files PCT Patent Application for Diabetic Symptoms

InnoCan Pharma Corporation Reports Positive Results from Recent Preclinical Trial on Epileptic Seizures on Dog Using LPT

Innocan Pharma Corporation Reports Successful Preclinical Dog-Trial Results Regarding Pain Management

Innocan Pharma Corporation Announces Filing of PCT Patent Application for Vaginal Atrophy Treatment

First quarter 2022 earnings released

Less than half of directors are independent

Companies Like InnoCan Pharma (CSE:INNO) Are In A Position To Invest In Growth

InnoCan Pharma Corporation Reports Successful FDA Required Characterization of Highly CBD Loaded Liposome Platform

Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

Innocan Pharma Corporation Cbd Integrated Anti-Aging Sleeping Mask Demonstrates A Reduction of the Appearance of Wrinkles by Up to 28.8% in 4 Weeks of Clinical Study

Innocan Pharma Corporation Completes a Cosmetic Clinical Study of SHIR® CBD Eye Serum on 22 Volunteers

Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment

Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study

Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study

We Think InnoCan Pharma (CSE:INNO) Needs To Drive Business Growth Carefully

Innocan Pharma Announces Patent Application for Novel Cannabis-Based Anti-Itch Treatment

InnoCan Pharma Corporation Announces the Completion of Its First Full-Scale Manufacturing Run in the US and the Launching of Its US Commercial Online Platform

Innocan Pharma Announces Successful Production of CBD Loaded Liposomes Under Aseptic Conditions

New 90-day high: CA$0.41

InnoCan Pharma Corporation Announces Successful Completion of a Large-Scale Production of Exosomes

InnoCan Pharma Corporation announced that it has received CAD 2.367804 million in funding

New 90-day high: CA$0.31

InnoCan Pharma Corporation Announces the Completion of Its First Full-Scale Manufacturing Run in Europe and the Commencement of its Full-Scale Manufacturing Run in the USA

Innocan Pharma Corporation Announces the Launch of Two Therapeutic Studies on Small and Large Animals Examining the Therapeutic Efficacy of CBD Loaded Liposome Platform Technology in Relevant Diseases

New 90-day high: CA$0.30

Innocan Pharma's Clinical Study in the US Indicates That More Than 90% of Participants Experienced Pain Reduction After Using Innocan's Relief & Go OTC Pain Relief Spray

Innocan Pharma's Cosmetic Clinical Study Indicates a 90% Wrinkle Reduction After Using Its SHIR(TM) Premium CBD Facial Serum

Innocan Pharma Corporation Provides Clinical Update of its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD